Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications
RSC Advances · 2026 · 16 (1) · 510-567
DOI: 10.1039/d5ra04838a ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Ancilla Dsouza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal Karnataka 576104 India nitin.shetty@manipal.edu. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
An overview of the role and current landscape of EGFR inhibitors in cancer treatment, with a particular emphasis on recent progress in the design, synthesis, and development of novel thiazole hybrid compounds as promising selective EGFR TKIs.
Autor:innen und Institutionen
- Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal Karnataka 576104 India nitin.shetty@manipal.edu.
- Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education Manipal Karnataka 576104 India.
ORCID-Profile: Nitinkumar S Shetty
Zitieren
APA
Dsouza, A., Subrahmanyam, V. M., & Shetty, N. S. (2026). Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications. RSC Advances, 16(1), 510-567. https://doi.org/10.1039/d5ra04838a
Vancouver
Dsouza A, Subrahmanyam VM, Shetty NS. Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications. RSC Advances. 2026;16(1):510-567. doi:10.1039/d5ra04838a
BibTeX
@article{Dsouza2026,
author = {Dsouza, Ancilla and Subrahmanyam, V M and Shetty, Nitinkumar S},
title = {Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {1},
pages = {510--567},
doi = {10.1039/d5ra04838a}
}
EUVIMED